SUVENPHAR2021-10-012021-12-31in-bse-fin:OneOperatingExpenses01Member SUVENPHAR2021-10-012021-12-31in-bse-fin:OneOperatingExpenses02Member SUVENPHAR2021-10-012021-12-31in-bse-fin:OneOperatingExpenses03Member SUVENPHAR2021-10-012021-12-31in-bse-fin:FourOperatingExpenses01Member SUVENPHAR2021-10-012021-12-31in-bse-fin:FourOperatingExpenses02Member SUVENPHAR2021-10-012021-12-31in-bse-fin:FourOperatingExpenses03Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares SUVENPHAR 2021-04-01 2022-03-31 2022-02-01 INR Lakhs Third quarter Single segment Contract Development and ManufacturingnOperations (CDMO) 2021-10-01 2021-12-31 Unaudited Consolidated 3915853000.00 646851000.00 4562704000.00 1184797000.00 0.00 9607000.00 250087000.00 7417000.00 105060000.00 611157000.00 2168125000.00 2394579000.00 0.00 2394579000.00 684336000.00 109553000.00 793889000.00 0.00 1600690000.00 0.00 0.00 0.00 0.00 1600690000.00 -2092000.00 1598598000.00 0.00 0.00 254565000.00 1 6.29 6.29 0.00 0.00 6.29 6.29 1) The above financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 8th Feb, 2022. The above results have been subjected to limited review by the statutory auditors of the company. 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder. 3) The consolidated financial results include the results of the wholly owned subsidiary Suven Pharma,Inc.,USA. 4) The Board has declared an interim Dividend of Rs.1.00 per equity share (100% of Face value of Rs.1.00 each) and one-time special dividend of Rs. 2.00 per equity share (200% of Face value of Rs.1.00), totalling to Rs. 3.00 per equity share (300% of Face value of Rs. 3.00 each) for the financial year 2021-22. 5) The Company reportable activity falls under single business segment and hence, segment reporting as per IND AS 108 (Operating Segment) is not presented. 6) The COVID-19 continuous to impact the business and research operations in India and our Wholly Owned Subsidiary, Suven Pharma, Inc., USA. Apart from the above the shortage or non-availability of vessels leading to delay in shipments, increase in transportation and distribution costs and timely non availability of materials with increase in materials costs are impacting our operations and profiability. 7) The other Income (Standalone figures for Q2-2021-22) includes an amount of Rs.3329.39 Lacs pertaining to the Dividends received from our Subsiadary. And also the Current tax (Standalone figures) includes an amount of Rs.491.72 lacs tax paid on Such Dividend by our subsidiary. 8) The Suven Pharma Inc., the WOS of our Company has divested it's entire stake (25% amounting to $35.00 Mn) in M/s Rising Pharma Holdings, Inc., USA on 13th Dec, 2021 to Raisin Acquisition Co, Inc., one of the investment arms of H.I.G. Capital, a leading global alternative investment firm in USA through structuered deal. As part of the structured deal our WOS, Suven Pharma, Inc., received in the form of cash component of $ 41.555 Mn and a stake valued at $15.803 Mn in Raisin Aggregators L.P. Accordingly, Rising Pharma Holdings, Inc., USA has ceased to be an associate company w.e.f 13th Dec, 2021. Hence, the share of profits of associate has not been considered in the consolidated financial statements for the Quarter ended 31st Dec, 2021 9) The Board has in today’s meeting held on 8th February, 2022, given its in-principle approval to evaluate the acquisition opportunity of Casper Pharma Pvt. Ltd. An SEZ company in Hyderabad engaged in Formulations. The Company will evaluate the proposal subject to financial, tax and legal due diligence to finalize the definitive agreements. 10) The corresponding previous period figures have been regrouped/reclassified where ever necessary. Single segment 2021-04-01 2021-12-31 Unaudited Consolidated 9563749000.00 755091000.00 10318840000.00 3291783000.00 0.00 -404118000.00 693619000.00 40423000.00 286763000.00 1758416000.00 5666886000.00 4651954000.00 0.00 4651954000.00 1307593000.00 134115000.00 1441708000.00 0.00 3210246000.00 0.00 0.00 0.00 411123000.00 3621369000.00 -6278000.00 3615091000.00 0.00 0.00 254565000.00 1 14.23 14.23 0.00 0.00 14.23 14.23 Manufacturing Expenses 462581000.00 Other Expense 126691000.00 R & D expenses 21885000.00 Manufacturing Expenses 1288452000.00 Other Expense 387861000.00 R & D expenses 82103000.00